LongueVue Capital portfolio company Pinnacle Clinical Research completes acquisitions of five clinical research sites
June 18, 2024
LongueVue Capital’s portfolio company Pinnacle Clinical Research has completed investments/acquisitions of five clinical research sites: Kerwin Medical Center, The Cognitive and Research Center of New Jersey, Bellaire Clinical Research, Palmetto Clinical Research – Low Country, and Dallas Research Institute. The additions broaden Pinnacle’s U.S. geographic footprint and expand therapeutic-area expertise, including central nervous system focus for Alzheimer’s disease indications via Kerwin Medical Center and CRCNJ.
- Targets
- Kerwin Medical Center, The Cognitive and Research Center of New Jersey, Bellaire Clinical Research, Palmetto Clinical Research - Low Country, Dallas Research Institute
- Platforms
- Pinnacle Clinical Research
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
BayPine to Acquire CenExel Clinical Research
April 14, 2025
Healthcare Services
BayPine entered into a definitive agreement to acquire CenExel Clinical Research, a nationwide clinical trial site network focused on complex therapeutic areas. After closing, BayPine will be the majority investor in CenExel alongside Webster Equity Partners, which will retain a minority stake, with management continuing to hold equity.
-
Summit Clinical Research (with Pinnacle) Acquires Houston Research Institute
February 28, 2025
Healthcare Services
LongueVue Capital portfolio company Summit Clinical Research, in partnership with Pinnacle Clinical Research, completed a strategic investment in Houston Research Institute (HRI) to expand Summit's metabolic/hepatology clinical research capabilities. The transaction brings HRI's scientific expertise into Summit/Pinnacle's site network and is accompanied by leadership additions — Dr. Mazen Noureddin named Co-Chairman (and Chief Scientific Officer), Dr. Naim Alkhouri as Chief Academic Officer, and Brandon Early as President.
-
Pinnacle Clinical Research Acquires Jubilee Clinical Research
September 27, 2024
Healthcare Services
LongueVue Capital-backed Pinnacle Clinical Research has acquired Jubilee Clinical Research, a Las Vegas-based multi-therapeutic clinical trial site focused on metabolic and cardiovascular indications. The add-on expands Pinnacle's West Coast footprint and therapeutic expertise; Jubilee's founder Dr. Elliot Shin will continue to lead the site within the Pinnacle network.
-
Pinnacle Clinical Research (LongueVue Capital) Combines with South Texas Research Institute
January 10, 2023
Healthcare Services
Pinnacle Clinical Research, a LongueVue Capital portfolio company, has completed a combination with South Texas Research Institute (STRI). The deal expands Pinnacle's clinical site network to six dedicated locations, strengthens recruitment capabilities (notably for NASH/NAFLD trials) and increases geographic reach into the Rio Grande Valley.
-
LongueVue Capital Invests in Pinnacle Clinical Research
November 16, 2022
Healthcare Services
LongueVue Capital, a New Orleans-based private equity firm, completed a growth investment in Pinnacle Clinical Research, a San Antonio-based multi-location clinical trial site network specializing in complex therapeutic areas including hepatology (NAFLD/NASH). The capital from LVC is intended to support Pinnacle’s organic and inorganic growth, expand clinical trial capacity, and enhance operational capabilities across its Texas sites.
-
LongueVue Capital Invests in Summit Clinical Research
October 26, 2022
Healthcare Services
LongueVue Capital completed a growth investment in Summit Clinical Research, an integrated research organization (IRO) headquartered in San Antonio, Texas. The investment will provide financial and human capital to accelerate Summit's growth and expand its clinical trial site network and capabilities, particularly in hepatology and NASH research.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.